Boehringer Ingelheim announced the first prescription issuance for Jascayd (nerandomilast tablets) in Shanghai, marking the commercial launch of the world’s first approved selective PDE4B inhibitor for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). The drug, which received China marketing authorization in October 2025, offers multifaceted anti-fibrotic, vascular protective, and immunomodulatory effects with a favorable safety profile designed to address the high discontinuation rates associated with existing therapies.
Global Strategy: U.S. FDA Breakthrough Therapy designation potential; EU EMA accelerated assessment
Forward‑Looking Statements This brief contains forward‑looking statements regarding commercial launch performance, global regulatory expansion, and competitive positioning for nerandomilast in pulmonary fibrosis. Actual results may differ due to reimbursement negotiations, physician adoption patterns, and competitive dynamics with established anti-fibrotic therapies.-Fineline Info & Tech
Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.
